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INTRODUCTION
Thyroid malignancies are the most common tumors of the endocrine system with ~45,000 newly diagnosed cases estimated in USA in 2010 (1) . Although thyroid cancer is often indolent, there is concern about its rapidly increasing incidence, especially amongst women (2) . Of the various histological sub-types, Papillary Thyroid Carcinoma (PTC) represents ~80% of all cases. Although surgery combined with radioiodine therapy is often curative, a better understanding of how thyroid cancer genetics influences the pathophysiology and therapy of this disease is required.
Of the somatic genetic alterations detected in PTC, mutational activation of BRAF is most common (~45%) and often associated with more aggressive disease (3) . As observed in melanoma and colon cancer, the most common mutation is a T1799→A tranversion in exon 15 that encodes BRAF V600E (4) . Once mutationally activated, the BRAF V600E ĺMEKĺERK MAP kinase signaling pathway elicits alterations in gene expression that contribute to the aberrant behavior of the cancer cell. Moreover, recent data suggest BRAF V600E is required for PTC maintenance since pharmacological inhibition of BRAF V600E by PLX-4032 in thyroid cancer patients led to tumor regression (5).
We have previously described the utility of BRaf CA mice carrying a Cre-activated allele of BRaf to model lung cancer (6) and melanoma (7) . Using mice with thyrocyte- architecture of thyroid follicles. Over a 6-9 month period all of these mice developed PTC displaying phenotypic characteristics of the cognate human disease. Moreover, treatment of the mice with a pharmacological MEK inhibitor elicited a striking reduction in thyroid size, restoration of thyroid hormone production and inhibition of tumorigenesis. Importantly, due to leaky activity of CreER T2 , untreated Thyro::CreER T2 ;
BRaf CA mice developed PTC without displaying hypothyroidism, albeit with delayed kinetics compared to tamoxifen treated mice. These data suggest that, unlike in the lung and skin where BRAF V600E induces a clearly defined stage of benign tumorigenesis, BRAF V600E can promote thyroid cancer progression without deliberate manipulation of tumor suppressor genes. Moreover, this system demonstrates utility in modeling the response of PTC to pharmacological inhibition BRAF V600E →MEK→ERK signaling.
MATERIALS AND METHODS

Mouse breeding and manipulation
BRaf CA mice were described previously (6, 7) . Thyroglobulin::CreER T2 (Thyro::CreER) mice were generated by conventional transgenic technology and will be described in full elsewhere (Amendola et al., Manuscript in preparation). Thyrocyte specific activation of CreER T2 activity was achieved by intraperitoneal injection of 100μl of a 10mg/ml stock of Tamoxifen dissolved in peanut oil into adult (~30 days old) mice.
Histology and Immunofluorescence of mouse thyroid tissue sections
Mice were euthanized by aortic dissection and thyroids removed, rinsed in ice cold PBS and fixed for 4 hours in Z-Fix (Anatech, MI, USA). 4-5μm sections of formalin fixed, paraffin embedded tissues were stained with Hematoxilin & Eosin or processed for immunofluorescence with epitope unmasking performed by boiling slides for 10 minutes (10mM Tris, 0.5mM EGTA pH 9.0). Primary antibodies were obtained from the listed commercial sources: α-TTF-1 (1:200, Santa Cruz), α-Ki67 (1:300, Abcam), α-CK19
(1:300, TROMA-III, Hybridoma bank, University of Iowa) and α-Galectin-3 (1:200, Abcam), α-HMGA2 (1:700, Biocheck, CA). Primary antibody binding was detected using either goat α-rabbit Alexa-488 (1:500) or goat α-rat Alexa-488 (1:500) (Molecular Probes) and then counter stained with DAPI.
Immunoblotting
Snap frozen thyroid specimens were extracted using a TissueLyser (Qiagen) in 1%(v/v) Triton-X, 20mM Hepes pH=9.0, 150mM NaCl, 10% (v/v) Glycerol, 1mM EDTA, 1mM EGTA buffer supplemented with Halt protease/phosphatase inhibitor cocktail (Pierce). Western blots of cell extracts were probed with α-pERK1/2 or α-total ERK1/2 (Cell Signaling Technology). Primary antibody binding was detected using goat α-rabbit IR800 or goat α-mouse IR680 1:15,000 (Li-Cor Bioscience) and imaged using a LI-COR Odyssey FC imager.
Serum TSH and T4 measurements
Mouse serum (0.5-1ml) was collected from retro-orbital bleeds at the time of euthanasia. Serum TSH and T4 was measured using specific radioimmune assays (National Hormone and Peptide Program, Harbor-UCLA Medical Center, Torrance, CA). 
Drug administrations
A suspension of the MEK1/2 inhibitor, PD0325901, was prepared by sonication in 0.5%(w/v) Hydroxy-Propyl-Methylcellulose (Sigma), 0.2%(v/v) Tween-80 that was prepared fresh every week. PD0325901 was administered to mice daily by oral gavage at 12.5mg/kg for 4 weeks. Triiodothyronine (T3 -Sigma) was supplemented into drinking water at 100ng/ml with 1%(w/v) sucrose. Effective daily dose was estimated at 100-200ng/mouse/day based on mouse water consumption of 1-2ml/day/mouse.
Ultrasound imaging
Mice were anesthetized using 2%(v/v) isofluorane and fur around the neck was removed using Veet£ depilatory cream. Ultrasound images were collected weekly using the Vevo770 system from VisualSonic. Thyroid size was assessed by counting pixels at the largest diameter of the thyroid using ImageJ (NIH) and converting pixel count into area (mm 2 ) using scaling software internal to the device. Differences in thyroid size were plotted in relation to the area of the largest diameter of the thyroid at the start of the drug administration period (d0) compared to the end (d32). we also detected a 100-fold increase in serum TSH at the same time points (Fig. 1D) . were randomly assigned into four treatment groups: Group 1 (4 mice) received vehicle control; Group 2 (5 mice) were administered with PD0325901 by oral gavage; Group 3 (4 mice) were treated with synthetic thyroid hormone (T3) in drinking water in an attempt to normalize TSH levels and; Group 4 (4 mice) were treated with a combination of PD325901 and T3. Treatments were administered for 1 month with effects on thyroid size monitored weekly (Fig. 5A ) by ultrasound imaging and enumerated by pixel counting as described in the Materials and Methods (Fig. 5B) . At the end of the treatment period mice were euthanized and their thyroid subject to histological analysis for the presence of PTC (Figs 5C). Serum TSH and T4 were analyzed as previously described (Fig. 5D) . The addition of T3 did not influence the reduction in thyroid size elicited by PD325901.
RESULTS
Expression
Results inferred by ultrasonography were confirmed by post-mortem analysis of thyroid size (data not shown). It should be noted that although the thyroid of PD325901 treated mice displayed a 60% decrease in relation to the starting size, they did not return to that of normal animals. Indeed, at the end of the treatment period, the thyroid of these animals remained approximately twice that of normal mice. Nevertheless, compared to vehicle or T3 treated mice, MEK1/2 inhibition had a dramatic inhibitory effect on the ability of BRAF V600E to promote increased thyroid size.
Histological analysis of the variously treated animals demonstrated that vehicle or T3
treated animals presented with PTC with characteristic cytological features and altered follicular architecture (Fig. 5C ) as described above (Fig. 1) . By contrast, and consistent with the inhibitory effects on thyroid size, PD325901 treated mice displayed a more normal appearing follicular architecture with an increased prevalence of normal follicles lined by cuboidal thyrocytes with no evidence of nuclear atypia (Fig. 5C) . Moreover, the follicles of PD325901 treated mice contained readily detectable eosinophilic colloid.
Although aberrant cells were not entirely eradicated from the thyroid of PD325901 Consistent with effects of PD325901 on thyroid size and architecture, treatment with PD325901 led to a normalization of serum T4 levels and a 6-fold decrease in serum TSH levels (Fig. 5D) showing at least partial restoration of thyroid endocrine function.
The effect of PD325901 on serum T4 and TSH was specific to mice with thyroid specific BRAF V600E expression (black bars) since similar treatment of control BRaf CA mice lacking the Thyro::CreER T2 transgene had no significant effect on either serum T4 or TSH levels (white bars). Single agent administration of T3 led to a decrease in serum TSH indicating that hormonal supplementation was at least partially effective.
Furthermore, mice administered with T3 plus PD325901 displayed very low serum T4 levels due to inhibitory effects of exogenous T3 on T4 production. A co-operative effect of PD325901 plus T3 is evidenced since co-administration led to an even more striking decrease in serum TSH than either agent alone. T3 administration showed that hormonal supplementation alone did not provide any therapeutic benefit unless coadministered with PD325901. Overall, these results demonstrate that the effects of BRAF V600E on thyroid function and tumorigenesis are highly reliant on MEK→ERK signaling.
DISCUSSION
Dysregulated RTK signaling, mediated by mutational activation of RET/PTC, K-or NRAS or BRAF, appears to be a feature common to the majority of thyroid cancers (16, 17 may be a more accurate model of human PTC since, under these circumstances, there is no goiter or hypothyroidism associated with PTC initiation or progression.
In previous studies we have documented that expression of BRAF V600E in the lung epithelium or in melanocytes leads to a distinct phase of benign tumorigenesis that fails to progress to malignancy unless tumor suppressor genes are deliberately silenced (6, 7). Furthermore, it has been proposed that BRAF V600E -induced benign tumorigenesis reflects the engagement of senescence as a cancer suppression mechanism (19, 20 
mechanism. It is possible that the 10-100 fold elevation of serum TSH might provide costimulatory signals through the heterotrimeric G-protein coupled TSH receptor that might prevent engagement of senescence mechanisms. Indeed, TSH receptor couples to cAMP production through activation of Gα s .GTP and to PI3'-kinase and/or PLCβ through βγ subunits. However, progression to PTC was detected in non-tamoxifen 
